We are a team with extensive experience in drug development from the pharmaceutical industry, focusing on discovery and development of novel small molecules.
We design and develop new organ-restricted chemical entities that addresses unmet medical needs in fibrosis and cancer.
read more
We focus on value creation through the design of novel chemical entities that modulate well validated targets in fibrosis and cancer.
Our strategy involves the development of organ-restricted compounds to maximize the potential of local TGF-β inhibition while sparing target-related toxicities, making TGF-β inhibitors a reality for patients.
We aim at harnessing the potential of well validated targets. Our current focus is the modulation of the TGF-β pathway, a key regulator of fibrosis development and immunosuppression.
Español
Galego